Fred Alger Management LLC Acquires 77,530 Shares of Repligen Corporation $RGEN

Key Points

• Fred Alger Management LLC increased its stake in Repligen Corporation by 21.6% in Q1, now holding 437,037 shares valued at approximately $55.6 million.
• Various institutional investors have also boosted their positions in Repligen, with 97.64% of the stock owned by such entities.
• Repligen's recent quarterly report showed earnings per share of $0.37, missing estimates, but revenue increased by 14.8% year-over-year to $182.37 million.

Fred Alger Management LLC lifted its position in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 21.6% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 437,037 shares of the biotechnology company's stock after buying an additional 77,530 shares during the quarter. Fred Alger Management LLC owned approximately 0.78% of Repligen worth $55,609,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Goldman Sachs Group Inc. grew its holdings in shares of Repligen by 16.8% during the first quarter. Goldman Sachs Group Inc. now owns 141,994 shares of the biotechnology company's stock worth $18,067,000 after buying an additional 20,375 shares in the last quarter. Jones Financial Companies Lllp boosted its position in shares of Repligen by 3,850.6% in the first quarter. Jones Financial Companies Lllp now owns 6,400 shares of the biotechnology company's stock worth $814,000 after acquiring an additional 6,238 shares during the last quarter. Dynamic Technology Lab Private Ltd boosted its position in shares of Repligen by 233.6% in the first quarter. Dynamic Technology Lab Private Ltd now owns 9,208 shares of the biotechnology company's stock worth $1,172,000 after acquiring an additional 6,448 shares during the last quarter. Scientech Research LLC acquired a new stake in shares of Repligen in the first quarter worth approximately $1,837,000. Finally, Alliancebernstein L.P. boosted its position in shares of Repligen by 1.3% in the first quarter. Alliancebernstein L.P. now owns 1,024,180 shares of the biotechnology company's stock worth $130,317,000 after acquiring an additional 13,284 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on RGEN shares. Stephens raised shares of Repligen to an "overweight" rating and set a $160.00 price target on the stock in a research report on Tuesday, July 22nd. HC Wainwright reaffirmed a "buy" rating and set a $180.00 price target on shares of Repligen in a research report on Wednesday, September 3rd. Evercore ISI reduced their price target on shares of Repligen from $140.00 to $130.00 and set an "in-line" rating on the stock in a research report on Tuesday, July 8th. Wells Fargo & Company reduced their price target on shares of Repligen from $180.00 to $175.00 and set an "overweight" rating on the stock in a research report on Wednesday, July 30th. Finally, Royal Bank Of Canada restated an "outperform" rating and issued a $205.00 price target on shares of Repligen in a research note on Tuesday, September 2nd. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $169.55.

Repligen Stock Up 1.3%

Shares of RGEN traded up $1.54 during trading hours on Wednesday, reaching $120.23. The company's stock had a trading volume of 986,487 shares, compared to its average volume of 663,220. The firm has a market cap of $6.76 billion, a price-to-earnings ratio of -480.90, a P/E/G ratio of 2.18 and a beta of 1.07. Repligen Corporation has a 1-year low of $102.96 and a 1-year high of $182.52. The company has a quick ratio of 7.32, a current ratio of 8.59 and a debt-to-equity ratio of 0.26. The company has a 50 day moving average of $121.16 and a two-hundred day moving average of $128.66.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share for the quarter, missing analysts' consensus estimates of $0.40 by ($0.03). The business had revenue of $182.37 million during the quarter, compared to analyst estimates of $174.62 million. Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. Repligen's revenue for the quarter was up 14.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.40 EPS. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. As a group, research analysts predict that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Insider Activity at Repligen

In other news, Director Martin D. Madaus purchased 1,800 shares of the stock in a transaction that occurred on Friday, August 8th. The stock was acquired at an average price of $112.13 per share, with a total value of $201,834.00. Following the purchase, the director owned 1,800 shares in the company, valued at $201,834. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.20% of the company's stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.